Abstract
IBZM-SPECT is useful as a predictor for the responsiveness to oral L-DOPA therapy in de novo parkinsonian patients. A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson's disease rather unlikely. Normal IBZM binding does not prove the diagnosis of Parkinson's disease; however, together with a positive apomorphine test, it strongly supports the clinical diagnosis. At present the combination of IBZM-SPECT and apomorphine testing appears to be a useful procedure for selecting de novo patients for clinical trials with new anti-parkinsonian therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Aged, 80 and over
-
Apomorphine*
-
Benzamides / pharmacokinetics*
-
Corpus Striatum / diagnostic imaging
-
Corpus Striatum / drug effects
-
Dopamine D2 Receptor Antagonists*
-
Female
-
Humans
-
Levodopa / therapeutic use*
-
Male
-
Middle Aged
-
Parkinson Disease / diagnostic imaging*
-
Parkinson Disease / drug therapy
-
Prospective Studies
-
Pyrrolidines / pharmacokinetics*
-
Receptors, Dopamine D1 / drug effects
-
Receptors, Dopamine D1 / physiology
-
Receptors, Dopamine D2 / physiology
-
Tomography, Emission-Computed, Single-Photon*
Substances
-
Benzamides
-
Dopamine D2 Receptor Antagonists
-
Pyrrolidines
-
Receptors, Dopamine D1
-
Receptors, Dopamine D2
-
Levodopa
-
3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
-
Apomorphine